Switchable genome editing via genetic code expansion

Suzuki T*, Asami M*, Patel SG, Luk LYP, Tsai YH, Perry ACF.

Scientific Reports volume 8, Article number: 10051 (2018)

Multiple applications of genome editing by CRISPR-Cas9 necessitate stringent regulation and Cas9 variants have accordingly been generated whose activity responds to small ligands, temperature or light. However, these approaches are often impracticable, for example in clinical therapeutic genome editing in situ or gene drives in which environmentally-compatible control is paramount. With this in mind, we have developed heritable Cas9-mediated mammalian genome editing that is acutely controlled by the cheap lysine derivative, Lys(Boc) (BOC). Genetic code expansion permitted non-physiological BOC incorporation such that Cas9 (Cas9BOC) was expressed in a full-length, active form in cultured somatic cells only after BOC exposure. Stringently BOC-dependent, heritable editing of transgenic and native genomic loci occurred when Cas9BOC was expressed at the onset of mouse embryonic development from cRNA or Cas9BOC transgenic females. The tightly controlled Cas9 editing system reported here promises to have broad applications and is a first step towards purposed, spatiotemporal gene drive regulation over large geographical ranges.

Schematic diagrams depicting natural translation and translation in the BOC system. (A) The natural incorporation of lysine (Lys, K) and (B) termination of translation at a stop codon. (C) When introduced ectopically, the orthogonal aminoacyl-tRNA synthetase, PylRS, can attach the non-physiological amino acid, BOC to its orthogonal tRNA, which decodes the stop codon, UAG, allowing BOC incorporation into a nascent polypeptide chain during translation. (D) Chemical structures of Lys and BOC.

Related article:

Asymmetric Parental genome engineering by Cas9 during mouse meiotic exit

Toru Suzuki*, Maki Asami* & Anthony C.F. Perry

*co-first author

Scientific Reports 4, Article number:7621 (2014)